Affordable Access

deepdyve-link
Publisher Website

LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway.

Authors
  • Wang, Guangyu
  • Li, Zhiwei
  • Zhao, Qi
  • Zhu, Yuanyuan
  • Zhao, Ci
  • Li, Xin
  • Ma, Zhigang
  • Li, Xiaobo
  • Zhang, Yanqiao
Type
Published Article
Journal
Oncology Reports
Publisher
Spandidos Publications
Publication Date
Apr 01, 2014
Volume
31
Issue
4
Pages
1839–1845
Identifiers
DOI: 10.3892/or.2014.3047
PMID: 24573322
Source
Medline
License
Unknown

Abstract

Recent studies show that long intergenic noncoding RNA-p21 (lincRNA-p21) is aberrantly expressed in several types of cancer, including colorectal cancer (CRC), one of the most common cancers in the world. Radiotherapy is considered as a standard preoperative treatment approach to reduce local recurrence for local advanced rectal cancer. However, a considerable number of rectal cancers are resistant to radiotherapy. In the present study, we evaluated the role of lincRNA‑p21 in radiotherapy for CRC and detected the possible molecular mechanism. By expression profile analysis, we demonstrated that lincRNA-p21 decreases in CRC cell lines and tissue samples, which contributes to the elevation of β-catenin in CRC. We further showed that lincRNA‑p21 increases following X-ray treatment, and enforced expression of the lincRNA enhances the sensitivity of radiotherapy for CRC by promoting cell apoptosis. Suppression of the β-catenin signaling pathway and elevation of the pro-apoptosis gene Noxa expression may help explain the role of lincRNA-p21 in CRC radiotherapy. The present study not only deepens our understanding of the mechanism of radiotherapy for CRC, but it also provides a potential target for CRC radiotherapy.

Report this publication

Statistics

Seen <100 times